E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114.
- DOI
- 10.1186/s13058-026-02295-8
- Published
- 2026 Sep 17
- Container
- Breast cancer research : BCR
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13058-026-02295-8,
title = {E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114.},
author = {Ishiguro H and Miyoshi Y and Yasojima H and Watanabe J and Takano T and Shimomura A and Tokunaga E and Mukohara T and Naoi Y and Matsuoka D and Okumura S and Otake Y and Suzuki T and Takase T and Semba T and Zhao Z and Yonemori K},
year = {2026},
journal = {Breast cancer research : BCR},
doi = {10.1186/s13058-026-02295-8},
url = {https://doi.org/10.1186/s13058-026-02295-8}
}RIS
TY - JOUR TI - E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114. AU - Ishiguro H AU - Miyoshi Y AU - Yasojima H AU - Watanabe J AU - Takano T AU - Shimomura A AU - Tokunaga E AU - Mukohara T AU - Naoi Y AU - Matsuoka D AU - Okumura S AU - Otake Y AU - Suzuki T AU - Takase T AU - Semba T AU - Zhao Z AU - Yonemori K PY - 2026 JO - Breast cancer research : BCR DO - 10.1186/s13058-026-02295-8 UR - https://doi.org/10.1186/s13058-026-02295-8 ER -
APA
H, I., Y, M., H, Y., J, W., T, T., A, S., E, T., T, M., Y, N., D, M., S, O., Y, O., T, S., T, T., T, S., Z, Z., & K, Y. (2026). E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114.. Breast cancer research : BCR. https://doi.org/10.1186/s13058-026-02295-8
Source records
- pubmed · retrieved 2026-09-25T20:51:23.560Z